
M2613 is a nonsteroidal estrogen derived from triphenylbromoethylene which was studied for the treatment of breast cancer in women in the 1940s, but was never marketed.[1] [2]
The chemical synthesis of M2613 has been described:[3]
The Grignard reaction between 1-(4-Ethoxyphenyl)-2-phenylethanone [38495-73-7] (1) and 4-Bromoanisole [104-92-7] (2) gives 3. Condensation with molecular bromine in the presence of glacial acetic acid completes the synthesis of M2613 (4). Alternately, Grignard reaction between 4-Ethoxy-4'-methoxybenzophenone [52886-92-7] (4) and benzyl bromide [100-39-0] (5) also yields 3.